Am J Transplant, Volume 5, Suppl 3 Archives - Page 48 of 170 - ATC Abstracts

2015 American Transplant Congress
Pertubations in the Urinary Exosome in Transplant Rejection
T. Sigdel,¹ Y. Ng,¹ S. Lee,² C. Nicora,³ W.-J. Qian,³ D. Camp II,³ M. Sarwal.¹
¹Surgery, UC San Francisco, San Francisco, CA; ²Nephrology, Kyung Hee University, Seoul, Korea; ³Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA.
Urine exosomes are small vesicles shed into the urine by exocytosis from all renal epithelial cell types under normal physiologic states and disease states, and…
2015 American Transplant Congress
Switching from Tacrolimus to Low-Dose Cyclosporine A Preserves Allograft Function in Presumptive and Definitive Polyomavirus-Associated Nephropathy
G. Huang, C.-X. Wang, J.-G. Fei, J. Qiu, S.-X. Deng, J. Li, G.-D. Chen, Q. Fu, R.-H. Deng, L.-Z. Chen.
Department of Organ Transplantation, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Switching from tacrolimus(Tac) to low-dose cyclosporine A(CsA) is recommended for preventing BK virus-associated nephropathy(BKVAN) and preserving allograft function in BKVAN patients, but systematic evaluations were…
2015 American Transplant Congress
Maintaining Immunosuppressive Treatment After Early Allograft Nephrectomy Does Not Reduce the Risk of Anti-HLA Allo-Sensitization
A. Del Bello,^1,2 N. Congy-Jolivet,^2,3,4 I. Cardeau-Desangles,¹ C. Guilbeau-Frugier,^2,5 E. Pambrun,¹ G. Dörr,¹ O. Milioto,⁶ L. Esposito,¹ L. Rostaing,^1,2,7 N. Kamar.^1,2,7
¹Nephrology, Dialysis and Organ Transplantation, CHU Rangueil, Toulouse, France; ²Université Paul Sabatier, Faculté de Médecine, Toulouse, France; ³Molecular Immunogenetics Laboratory, EA 3034, Faculté de Médecine Purpan, IFR150, Toulouse, France; ⁴Department of Immunology, CHU Rangueil, Toulouse, France; ⁵Department of Pathology, CHU Rangueil, Toulouse, France; ⁶Nephrology, Clinique Saint-Exupery, Toulouse, France; ⁷INSERM U1043, IFR–BMT, CHU Purpan, Toulouse, France.
BackgroundAnti-HLA immunization is greatly increased after early kidney-allograft failure, even if the graft is removed within a few hours post-transplantation. The aim of our study…
2015 American Transplant Congress
Assessing Transplant Attitudes: Understanding Minority Men's Perspectives on the Multifarious Barriers to Organ Donation
B. Hinck, B. Naelitz, B. Jackson, M. Howard, A. Nowacki, C. Modlin.
Glickman Urologic and Kidney Institute - Minority Men's Health Center, Cleveland Clinic, Cleveland, OH.
African-Americans comprise 13% of the US population; yet compose 34% of the kidney transplant waiting list and only 14% of cadaveric donors and 11% of…
2015 American Transplant Congress
Viral Prophylaxis Is Unnecessary in CMV Low Risk Kidney Transplant Recipients Who Receive Lymphocyte Depleting Induction
M. Gillespie,¹ B. Sirandas,² A. Carlson,² S. Lee,³ L. Smith.²
¹Pharmacy, University of Maryland, Baltimore; ²Transplant, University of Utah, Salt Lake City; ³Transplant, University of Southern California, Los Angeles.
Background: Both the international CMV consensus and AST guidelines recommend against the routine use of CMV prophylaxis in CMV D-/R- kidney transplant recipients (KTR), but…
2015 American Transplant Congress
Are AT1R Antibodies as Dangerous as HLA-DSAs in Renal Allografts?
E. Cuevas, J. Arreola-Guerra, E. Hernandez-Mendez, I. Salcedo, M. Vilatoba, A. Contreras, A. Sanchez-Cedillo, J. Ramirez, D. de Rungs, J. Granados, L. Morales-Buenrostro, J. Alberu.
1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Distrito Federal, Mexico.
Angiotensin II type 1 receptor antibodies (AT1Rab) have been associated with a significantly lower graft survival and a higher risk of acute rejection after kidney…
2015 American Transplant Congress
Repeat Donor HLA Mismatch Antigens and Kidney Transplant Outcome
P. Lokhandwala,¹ M. Wang,² Z. Kadry,³ R. Shah,³ A. Jain,³ J. Gaspari,¹ N. Ghahramani,⁴ C. Abendroth,¹ H. Shike.¹
¹Pathology, Penn State Hershey Medical Center, Hershey, PA; ²Public Health Sciences, Penn State College of Medicine, Hershey; ³Transplant Surgery, PSHMC, Hershey; ⁴Nephrology, PSHMC, Hershey.
Background: Historically, poorer outcome has been reported in kidney re-transplant patients with repeat HLA mismatch antigens. Transplant practice has evolved. Risk of repeat mismatch antigen…
2015 American Transplant Congress
Impact of Pre-Transplant Panel Reactive Antibody Levels On Renal Graft Survival in Patients With Negative Cross-Match and No Donor Specific Antibody
K. Jun,¹ M. Kim,¹ H. Kim,¹ K. Park,² S. Ahn,¹ J. Hwang,¹ S. Kim,¹ S. Park,¹ S. Kim,¹ J. Kim,¹ I. Moon.¹
¹Vascular and Transplant Surgery, The Catholic University of Korea, Seoul, Korea; ²Vascular Surgery, Inha University, Incheon, Korea.
Purposes: This study was conducted to investigate the impact of pre-transplant PRA level on rejection and graft survival after kidney transplantation in patients with negative…
2015 American Transplant Congress
Outcomes in Kidney Transplant Recipients Over Age of 55 by Donor Source: LD, SCD, ECD
V. Kirchner, K. Gillingham, A. Matas, The Div of Tx and Tx Nephrology.
University of Minnesota, Mpls.
Background: Outcomes in older kidney transplant recipients from SCD and ECD have been studied; however, comparative outcomes between older recipients of LD, SCD and ECD…
2015 American Transplant Congress
Infections After Alemtuzumab Induction: A Non Issue?
A. Smith, M. John, I. Dortonne, A. Paramesh, M. Killackey, R. Zhang, B. Lee, J. Buell.
Transplant Institute, Tulane University, New Orleans, LA.
Background: Alemtuzumab is a powerful induction agent that depletes multiple lymphocyte cell lines resulting in leukopenia and/or neutropenia with concerns over infectious complications. This study…